Bristol-Myers 4Q net rises 9 pct on cost cuts San Antonio Express However, transplant rejection drug Nulojix, approved in June 2011, generated just $4 million in the fourth quarter and $11 million for all of 2012. "Bristol-Myers Squibb had a strong finish to an important year of transition," CEO Lamberto Andreotti ... |
